US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026

Abstract
"US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

• US Transdermal Patch Market Insight
• US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
• Number of Patch In Clinical Trials: > 40 Patch
• Availability, Dosage & Price Analysis On 20 Patches Approved by FDA
• Marketed Transdermal Patch Clinical Insight: > 25 FDA Approved Patch
• Value Chain Analysis for US Transdermal Patch Market
• US Transdermal Patch Market Opportunity Assessment by Indication

Transdermal patch market consists of a non invasive method of introducing desirable drug into the body of the patient. In past few years, this respective mode of drug delivery which is painless and non-invasive has become one of the most attractive mode of drug delivery. The same has also been classified as one of the most innovative and classic therapeutics sectors in the entire pharmaceutical market. Drug delivery market is packed with tons of application-based methods of delivering desired drug into the patients, but the total appreciation and adoption rate received by transdermal patch from the researchers and the patients have conventionally transformed the entire market into one of the most desirable therapeutics market with a market size worth billions of dollars.

"US Transdermal Patch Market Opportunity Will Surpass USD 6 Billion In Next Few Years Driven By Technology Innovation And Increasing Acceptability Toward Patch Drug Delivery Methodology"

Only transdermal patch drug delivery market is classified as one of the most pivotal contribution to the general pharmaceutical market as the market consists of attaching a patch to the desired part of the body, letting the drug to release inside the body in a controlled manner. Therefore, it can be recorded that the therapy in an indirect way has also been responsible for boosting the controlled drug delivery market trends and opportunities. The US transdermal patch drug delivery market is also associated with large number of major key players inclined towards developing transdermal patches for different diseases. In addition, continuous research and development strategies opted by the focused researchers towards adding novel techniques to it is also believed to be adding prominent drivers to the market.

"More Than 25 FDA Approved Patches Are Available In The US Market And More Than 40 Are In Clinical Trials"

There are numerous advantages that are observed within the therapy. Some of the application-based advantages associated with the therapy are: painless, non-invasive, convenient, release of desirable disease and many more. The ultimate exposure of the drug through transdermal patches is also leading to high rate of consumption of the drugs as well as extensive survival rate of the patients suffering from different types of diseases. The respective market for drug delivery is also witnessed to be dominating the other drug delivery markets that are present in the pharmaceutical industry for long period of time.

As per "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report findings, it is estimated that for more than two or three decades from now, the respective market in the US will continue to dominate the entire pharmaceutical market in the world. Looking forward, the robust and strong clinical pipeline associated with the market at pre-clinical and clinical level for different diseases such as cancer and many more are estimated to yield more specific trends that are never observed in the pharmaceutical market at global level. The entire navigation of the US researchers towards the urgent need of an efficient drug delivery system and having a prominent non-invasive technique for eradicating the disease-causing cells from the body of the patient. As per the analysis done for the US transdermal patch market, it is believed that in the next few years, the US market will be identifying several drugs for different diseases that could be administered inside the body with the aid of transdermal patches, compared with early 2000’s.

Content
1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine & Female Contraceptive Transdermal
Patch

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. US Transdermal Patch Market Overview
6.1 Current Market Scenario
6.2 US Transdermal Patch Clinical Pipeline Overview
6.2.1 By Company
6.2.2 By Drug Class
6.2.3 By Indication
6.2.4 By Phase

7. Generic & Branded Transdermal Patches
 
8. Value Chain Analysis for Transdermal Patch Market
8.1 Research & Development
8.2 Manufacturing
8.3 Marketing & Distribution
8.4 Price to End User

9. US Transdermal Patch Contract Manufacturing Organization (CMO)

10. Transdermal Patches for Cardiovascular Diseases - US Market Availability, Dosage & Price Analysis
10.1 Clonidine Transdermal Patch (Catapres–TTS)
10.2 Nitro Glycerin Transdermal Patch
10.2.1 Nitro-Dur
10.2.2 Nitro TD Patch A
10.2.3 Generic Nitroglycerine Transdermal Patch

11. Opioid Drug Containing Transdermal Patches - US Market Availability, Dosage & Price Analysis
11.1 Fentanyl Transdermal Patch (Duragesic)
11.2 Buprenorphine Transdermal Patch (Butrans Patch)

12. Transdermal Patches for Neurological Disorders - US Market Availability, Dosage & Price Analysis
12.1 Selegiline Transdermal Patch (Emsam)
12.2 Scopolamine Transdermal Patch (Transderm-Scop)
12.3 Rivastigmine Transdermal Patch (Exelon)
12.4 Methylphenidate Transdermal Patch (Daytrana)
12.5 Asenapine Transdermal Patch (Secuado)
12.6 Rotigotine Transdermal Patch (Neupro)
 
13. Transdermal Patch in Hormonal Therapy - US Market Availability, Dosage & Price Analysis
13.1 Estradiol Transdermal Patch
13.1.1 Alora
13.1.2 Vivelle-Dot
13.1.3 Minivelle
13.1.4 Climara
13.1.5 Generic Estradiol Transdermal Patch
13.2 Testosterone Transdermal Patch (Androderm)
13.3 Ethinyl Estradiol & Norelgestromin Transdermal Patch
13.3.1 Xulane
13.3.2 Combipatch
13.4 Estradiol/Levonorgestrel Transdermal Patch (Climara Pro)
13.5 Ethinyl Estradiol/Levonorgestrel (Twirla)

14. Transdermal Patches for Other Conditions - US Market Availability, Dosage & Price Analysis
14.1 Nicotine Transdermal Patch (Nicoderm CQ/Harbitrol)
14.2 Oxybutynin Transdermal Patch (Oxytrol)
14.3 Sancuso (Granisetron)

15. US - Transdermal Patch Clinical Pipeline By Company, Indication & Phase
15.1 Research
15.2 Preclinical
15.3 Clinical
15.4 Phase-I
15.5 Phase-I/II
15.6 Phase-II
15.7 Phase-III
15.8 Preregistration
15.9 Registered
 
16. US - Marketed Transdermal Patch Clinical Insight by Company & Indication

17. US Transdermal Patch Market Opportunity Assessment
17.1 Parkinson’s Disease
17.2 Alzheimer's Disease
17.3 Female Contraceptive
17.4 Nicotine Replacement Therapy
17.5 Cardiovascular Disease
17.6 Insulin
17.7 Vaccine

18. US Transdermal Patch Market Dynamics
18.1 Favorable Market Parameters
18.2 Commercialization Challenges

19. US Transdermal Patch Market Future Prospects

20. Competitive Landscape
20.1 3M Pharmaceuticals
20.2 Acrux
20.3 Agile Therapeutics
20.4 Allergan
20.5 ANI Pharmaceuticals
20.6 Antares Pharma
20.7 Bayer HealthCare Pharmaceuticals
20.8 Corium International
20.9 Chase Pharmaceuticals
20.10 DURECT Corporation
20.11 Endo Pharmaceuticals
20.12 Fempharm
20.13 Hisamitsu Pharmaceutical
20.14 Immune Pharmaceuticals
20.15 Imprimis Pharmaceuticals
20.16 Ipsen Bioscience
20.17 Johnson & Johnson
20.18 LaSalle Laboratories
20.19 Lavipharm-increase
20.20 MINRAD International
20.21 NeurogesX
20.22 Noven Pharmaceuticals
20.23 NuPathe
20.24 Nuvo Research
20.25 Novartis
20.26 Pain Therapeutics
20.27 ProStrakan
20.28 Purdue Pharma
20.29 Sanofi
20.30 Scilex Pharmaceuticals
20.31 Senju Pharmaceutical
20.32 Somerset Pharmaceuticals
20.33 Teikoku Seiyaku
20.34 Therapeutic Discovery Corporation
20.35 Transdermal Delivery Solutions Corp
20.36 UCB-full form
20.37 Xel Pharmaceuticals
20.38 Zosano Pharma

List of Tables
Table 2-1: Differences between Active & Passive Transdermal Patches

Table 4-1: Transdermal Patches for Various Disease Indications

Table 6-1: Features Required in Transdermal Patches
Table 6-2: US - Different Transdermal Drug Delivery Systems Available in Market

Table 7-1: Similarities & Difference Between Generic & Branded Transdermal Patches
Table 7-2: US - Some Generic Transdermal Patches Available in Market

Table 8-1: Breakdown of Transdermal Patch Value Chain Analysis

Table 11-1: Duragesic - Initial Dose Conversion from Other Opioids
Table 11-2: Butrans – Initial Dose Calculation using Previous Opioid (Morphine) Dosage

Table 12-1: Daytrana - Dose Increment Pattern for Treatment of ADHD

Table 17-1: US - Estimated Adoption Rates for Parkinson's Disease Transdermal Patches, 2021-2026
Table 17-2: Description of Neupro Patch for Parkinson’s Disease
Table 17-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer's Disease, 2021-2026
Table 17-4: Transdermal Patches for Alzheimer’s Disease
Table 17-5: Description of Ortho Evra Contraceptive Patch
Table 17-6: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 17-7: Clonidine Patch - Difference Between Generic & Branded Transdermal Patch
Table 17-8: US - Estimated Adoption Rates for Hypertension Transdermal Patches, 2021-2026
Table 17-9: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2021-2026
Table 17-10: US - Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2021-2026

Table 20-1: Pain Therapeutics Clinical Pipeline